Lee S Newman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11734351/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Sarcoidosis. New England Journal of Medicine, 1997, 336, 1224-1234.	27.0	1,271
2	A Case Control Etiologic Study of Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1324-1330.	5.6	612
3	Human health risk assessment of air emissions from development of unconventional natural gas resources. Science of the Total Environment, 2012, 424, 79-87.	8.0	472
4	HLA-DRB1*1101: A Significant Risk Factor for Sarcoidosis in Blacks and Whites. American Journal of Human Genetics, 2003, 73, 720-735.	6.2	342
5	Birth Outcomes and Maternal Residential Proximity to Natural Gas Development in Rural Colorado. Environmental Health Perspectives, 2014, 122, 412-417.	6.0	275
6	Epidemiology of Beryllium Sensitization and Disease in Nuclear Workers. The American Review of Respiratory Disease, 1993, 148, 985-991.	2.9	206
7	Pathologic and Immunologic Alterations in Early Stages of Beryllium Disease: Re-examination of Disease Definition and Natural History. The American Review of Respiratory Disease, 1989, 139, 1479-1486.	2.9	198
8	Differential expression of lymphocyte homing receptors by human memory/effector T cells in pulmonary versus cutaneous immune effector sites. European Journal of Immunology, 1994, 24, 1269-1277.	2.9	189
9	Machining risk of beryllium disease and sensitization with median exposures below 2 ?g/m3. , 1996, 30, 16-25.		174
10	Beryllium Sensitization Progresses to Chronic Beryllium Disease. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 54-60.	5.6	157
11	Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease. Journal of Allergy and Clinical Immunology, 1991, 88, 54-60.	2.9	145
12	Screening Blood Test Identifies Subclinical Beryllium Disease. Journal of Occupational and Environmental Medicine, 1989, 31, 603-608.	1.7	143
13	Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2003, 20, 204-11.	0.2	122
14	Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups. Human Molecular Genetics, 2010, 19, 4100-4111.	2.9	121
15	Nonoccupational Beryllium Disease Masquerading as Sarcoidosis: Identification by Blood Lymphocyte Proliferative Response to Beryllium. The American Review of Respiratory Disease, 1992, 145, 1212-1214.	2.9	89
16	Beryllium exposure and chronic beryllium disease. Lancet, The, 2004, 363, 415-416.	13.7	82
17	Target organ localization of memory CD4+ T cells in patients with chronic beryllium disease. Journal of Clinical Investigation, 2002, 110, 1473-1482.	8.2	82
18	Beryllium Particulate Exposure and Disease Relations in a Beryllium Machining Plant. Journal of Occupational and Environmental Medicine, 2001, 43, 238-249.	1.7	80

LEE S NEWMAN

#	Article	IF	CITATIONS
19	Expansions of T-cell Subsets Expressing Particular T-cell Receptor Variable Regions in Chronic Beryllium Disease. American Journal of Respiratory Cell and Molecular Biology, 1998, 18, 581-589.	2.9	79
20	Efficacy of Serial Medical Surveillance for Chronic Beryllium Disease in a Beryllium Machining Plant. Journal of Occupational and Environmental Medicine, 2001, 43, 231-237.	1.7	73
21	Beryllium sensitivity is linked to HLA-DP genotype. Toxicology, 2001, 165, 27-38.	4.2	70
22	Early Pulmonary Physiologic Abnormalities in Beryllium Disease. The American Review of Respiratory Disease, 1993, 148, 661-666.	2.9	68
23	Mycobacterial antigens may be important in sarcoidosis pathogenesis. Current Opinion in Pulmonary Medicine, 2006, 12, 359-363.	2.6	66
24	Target organ localization of memory CD4+ T cells in patients with chronic beryllium disease. Journal of Clinical Investigation, 2002, 110, 1473-1482.	8.2	57
25	Chronic Beryllium Disease: T Cell Recognition of a Metal Presented by HLA-DP. Clinical Immunology, 2001, 100, 4-14.	3.2	56
26	Mycobacterial ESAT-6 and katG are Recognized by Sarcoidosis CD4+ T Cells When Presented by the American Sarcoidosis Susceptibility Allele, DRB1*1101. Journal of Clinical Immunology, 2010, 30, 157-166.	3.8	56
27	The Use of Health Impact Assessment for a Community Undergoing Natural Gas Development. American Journal of Public Health, 2013, 103, 1002-1010.	2.7	52
28	Frequency of beryllium-specific, central memory CD4+ T cells in blood determines proliferative response. Journal of Clinical Investigation, 2005, 115, 2886-2893.	8.2	52
29	Inorganic Dust Pneumonias: The Metal-Related Parenchymal Disorders. Environmental Health Perspectives, 2000, 108, 685.	6.0	51
30	Occupational interstitial lung disease. Clinics in Chest Medicine, 2004, 25, 467-478.	2.1	49
31	TGF-β1 Variants in Chronic Beryllium Disease and Sarcoidosis. Journal of Immunology, 2007, 179, 4255-4262.	0.8	47
32	CD28 costimulation independence of target organ versus circulating memory antigen-specific CD4+ T cells. Journal of Clinical Investigation, 2003, 112, 776-784.	8.2	45
33	Comparison of Sarcoidosis Phenotypes Among Affected African-American Siblings. Chest, 2006, 130, 855-862.	0.8	43
34	Gene-environment interactions in sarcoidosis: challenge and opportunity. Clinics in Dermatology, 2007, 25, 267-275.	1.6	43
35	Risk of Chronic Beryllium Disease by HLA-DPB1 E69 Genotype and Beryllium Exposure in Nuclear Workers. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1680-1688.	5.6	43
36	Chronic beryllium disease: a model interaction between innate and acquired immunity. International Immunopharmacology, 2002, 2, 249-261.	3.8	42

LEE S NEWMAN

#	Article	IF	CITATIONS
37	Frequency of beryllium-specific, T1-type cytokine-expressing CD4 T cells in patients with beryllium-induced disease. Journal of Allergy and Clinical Immunology, 2005, 115, 1036-1042.	2.9	42
38	Beryllium Skin Patch Testing to Analyze T Cell Stimulation and Granulomatous Inflammation in the Lung. Journal of Immunology, 2002, 168, 3627-3634.	0.8	41
39	Serum Angiotensin Converting Enzyme Activity in Chronic Beryllium Disease. The American Review of Respiratory Disease, 1992, 146, 39-42.	2.9	39
40	Aerosols Generated During Beryllium Machining. Journal of Occupational and Environmental Medicine, 2000, 42, 8.	1.7	39
41	Identification of an abnormal beryllium lymphocyte proliferation test. Toxicology, 2003, 183, 39-56.	4.2	37
42	Beryllium-Induced Tumor Necrosis Factor-α Production by CD4+T Cells Is Mediated by HLA-DP. American Journal of Respiratory Cell and Molecular Biology, 2004, 31, 122-130.	2.9	35
43	Comparison of In Vivo and In Vitro Measures of Beryllium Sensitization. Journal of Occupational and Environmental Medicine, 1997, 39, 540-547.	1.7	33
44	Beryllium Medical Surveillance at a Former Nuclear Weapons Facility During Cleanup Operations. Journal of Occupational and Environmental Medicine, 2004, 46, 953-961.	1.7	32
45	Beryllium-Ferritin. American Journal of Respiratory Cell and Molecular Biology, 2004, 31, 470-477.	2.9	31
46	Secondary Ion Mass Spectroscopy Demonstrates Retention of Beryllium in Chronic Beryllium Disease Granulomas. Journal of Occupational and Environmental Medicine, 2005, 47, 1218-1226.	1.7	31
47	Beryllium lymphocyte proliferation test surveillance identifies clinically significant beryllium disease. American Journal of Industrial Medicine, 2009, 52, 762-773.	2.1	31
48	CD28 costimulation independence of target organ versus circulating memory antigen-specific CD4+ T cells. Journal of Clinical Investigation, 2003, 112, 776-784.	8.2	31
49	Exposure and genetics increase risk of beryllium sensitisation and chronic beryllium disease in the nuclear weapons industry. Occupational and Environmental Medicine, 2011, 68, 842-848.	2.8	29
50	Lung Fibrosis in Plutonium Workers. Radiation Research, 2005, 164, 123-131.	1.5	28
51	Significance of the Blood Beryllium Lymphocyte Proliferation Test. Environmental Health Perspectives, 1996, 104, 953.	6.0	27
52	Immunology, Genetics, and Epidemiology of Beryllium Disease. Chest, 1996, 109, 40S-43S.	0.8	26
53	Beryllium-specific CD4+ T cells in blood as a biomarker of disease progression. Journal of Allergy and Clinical Immunology, 2011, 128, 1100-1106.e5.	2.9	26
54	The Natural History of Beryllium Sensitization and Chronic Beryllium Disease. Environmental Health Perspectives, 1996, 104, 937.	6.0	24

LEE S NEWMAN

#	Article	IF	CITATIONS
55	Serum neopterin in chronic beryllium disease. , 1997, 32, 21-26.		16
56	Beryllium-stimulated neopterin as a diagnostic adjunct in chronic beryllium disease. American Journal of Industrial Medicine, 2003, 43, 592-601.	2.1	16
57	Beryllium-stimulated in vitro migration of peripheral blood lymphocytes. Toxicology, 1999, 138, 155-163.	4.2	15
58	Beryllium-Induced TNF-α Production Is Transcription-Dependent in Chronic Beryllium Disease. American Journal of Respiratory Cell and Molecular Biology, 2007, 36, 191-200.	2.9	14
59	Birth Outcomes and Natural Gas Development: McKenzie et al. Respond. Environmental Health Perspectives, 2014, 122, A232-3.	6.0	14
60	Sulfasalazine and Mesalamine Modulate Beryllium-Specific Lymphocyte Proliferation and Inflammatory Cytokine Production. American Journal of Respiratory Cell and Molecular Biology, 2010, 43, 458-464.	2.9	6
61	Accelerator mass spectrometry detection of beryllium ions in the antigen processing and presentation pathway. Journal of Immunotoxicology, 2015, 12, 181-187.	1.7	1
62	CpG promoter methylation status is not a prognostic indicator of gene expression in beryllium challenge. Journal of Immunotoxicology, 2016, 13, 417-427.	1.7	1
63	Pathologic and Immunologic Alterations in Early Stages of Beryllium Disease: Re-examination of Disease Definition and Natural History. The American Review of Respiratory Disease, 1989, 140, 1834-1835.	2.9	Ο
64	On the Differential Diagnosis of Chronic Beryllium Disease and Sarcoidosis: Reply. The American Review of Respiratory Disease, 1990, 142, 739-740.	2.9	0
65	Occupational Interstitial Lung Disease Update. , 2009, , 195-211.		0

66 Human Berylliosis. , 0, , 245-264.

0